Credit Suisse’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-88,987
| Closed | -$30K | – | 4372 |
|
|
2016
Q3 | $30K | Sell |
88,987
-48,689
| -35% | -$16.4K | ﹤0.01% | 4047 |
|
|
2016
Q2 | $64K | Buy |
137,676
+124,163
| +919% | +$57.7K | ﹤0.01% | 4126 |
|
|
2016
Q1 | $18K | Sell |
13,513
-46,210
| -77% | -$61.6K | ﹤0.01% | 3932 |
|
|
2015
Q4 | $88K | Buy |
59,723
+14,515
| +32% | +$21.4K | ﹤0.01% | 4083 |
|
|
2015
Q3 | $71K | Sell |
45,208
-4,510
| -9% | -$7.08K | ﹤0.01% | 4146 |
|
|
2015
Q2 | $85K | Sell |
49,718
-12,437
| -20% | -$21.3K | ﹤0.01% | 4408 |
|
|
2015
Q1 | $86K | Sell |
62,155
-141,558
| -69% | -$196K | ﹤0.01% | 4241 |
|
|
2014
Q4 | $307K | Buy |
203,713
+130,091
| +177% | +$196K | ﹤0.01% | 4043 |
|
|
2014
Q3 | $151K | Buy |
73,622
+11,886
| +19% | +$24.4K | ﹤0.01% | 4226 |
|
|
2014
Q2 | $189K | Sell |
61,736
-358,091
| -85% | -$1.1M | ﹤0.01% | 4391 |
|
|
2014
Q1 | $1.05M | Buy |
419,827
+344,186
| +455% | +$861K | ﹤0.01% | 3076 |
|
|
2013
Q4 | $375K | Sell |
75,641
-36,109
| -32% | -$179K | ﹤0.01% | 3930 |
|
|
2013
Q3 | $255K | Buy |
111,750
+69,316
| +163% | +$158K | ﹤0.01% | 3868 |
|
|
2013
Q2 | $94K | Buy |
+42,434
| New | +$94K | ﹤0.01% | 4029 |
|
Credit Suisse's RXII Position: Q4 2016 in Review
Credit Suisse sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 88,987 shares — an estimated $30K sold.
Credit Suisse first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $1.05M in Q1 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Credit Suisse reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Credit Suisse sold 88,987 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $30K.
- Credit Suisse first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Credit Suisse's GALENA BIOPHARMA INC COM position peaked at $1.05M in Q1 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.